and increased survival has been shown in one subgroup of patients. 4 Lung volume reduction surgery is among the most carefully studied operations in medicine, having been subjected to many randomised controlled trials, all of which established its eff ectiveness. [4] [5] [6] [7] [8] However, as with all operations, lung volume reduction surgery engenders some risk. To receive the benefi ts, even appropriate candidates for lung volume reduction surgery must accept a 3-4% risk of perioperative death, 4 a 1-2 week hospitalisation, and a several week period of recovery. Thus, there has been an eff ort to try to reduce the risk of lung volume reduction surgery and achieve the same physiological benefi ts by less invasive approaches.
The best studied non-surgical approach to lung volume reduction is bronchoscopic placement of oneway endobronchial valves (bronchoscopic lung volume reduction) designed to shut down air infl ow to a segment or lobe, thereby allowing that region to collapse. Randomised studies with these valves, however, have shown very disappointing mean group improvements in various measures of lung function. These studies showed statistically, but not clinically, signifi cant changes when all patients were analysed. [9] [10] [11] Post-hoc analyses have suggested, not surprisingly, that those with markedly heterogeneous disease and complete interlobar fi ssures (which do not allow collateral ventilation across them) improve more with valves than do other patients.
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In The Lancet, Claire Davey and colleagues 12 compare bronchoscopic lung volume reduction with sham bronchoscopy in a randomised trial comprising 50 patients with heterogeneous emphysema and intact interlobar fi ssures. The authors show convincingly that prospective selection of patients with heterogeneous disease and minimal collateral ventilation yields substantially greater improvements than treatment of those without these characteristics. Although the results are not quite as impressive as in the post-hoc analysis of Sciurba and colleagues' study, 11 the present trial does show a median 8·77% (IQR 2·27-35·85) improvement in FEV 1 after unilateral valve placement, as well as signifi cant improvements in exercise capacity (the higher mean improvement in FEV 1 of 24·8% is skewed by a few high-responding outliers). Extrapolation, however unscientifi c, to expect a nearly doubled eff ect if bronchoscopic lung volume reduction is done bilaterally might achieve results that are perhaps half of what can be achieved by surgery (18% improvement in FEV 1 with valves vs 30-50% with surgery).
We declare no competing interests. There are some real strengths to Davey and colleagues' study. 12 The design is impressive in its inclusion of sham bronchoscopy in the control group. Very few studies of invasive procedures in medicine have included an actual operated sham group. This truly double-masked design meets the most stringent defi nition of a high quality clinical trial. It is also notable that the study was funded by the UK Medical Research Council rather than the commercial producer of the valve, eliminating the potential for commercial bias, which has been present in many previous studies of endobronchial valves, nearly entirely.
Some very important fi ndings, however, deserve to be more clearly highlighted. First, Davey and colleagues' study 12 does not bear out the expectation that bronchoscopic lung volume reduction is substantially less morbid that surgical lung volume reduction. In fact, two (8%) of the patients in the bronchoscopic lung volume reduction group died after the procedure (vs none in the control group). This death rate is higher than the perioperative death rate in nearly all modern surgical series of bilateral surgical lung volume reduction surgery. Although not statistically diff erent between groups, there was also an apparent increase in respiratory and infectious complications in the valve patients: two patients needed valve removal, four expectorated a valve, two had pneumonia (vs zero controls), and two suff ered pneumothorax (vs one control). It might be that the better lobar isolation achieved in these patients with intact fi ssures led to more trouble as well as more benefi t. These problems could explain why, despite the improvements in FEV 1 , the St George's Respiratory Questionnaire scores were no better in treated patients than in controls.
Worse, would the rates of each of these problems be doubled if the bronchoscopic lung volume reduction procedure was done bilaterally, as would probably be needed for improvements after the procedure to reach the same ballpark as surgical results? Doubling an 8% mortality reaches a higher death rate than has been seen in any published series of surgical lung volume reduction other than the publication that defi ned the high-risk subgroup within the NETT trial 13 -a group which now never undergoes the operation.
Lung volume reduction surgery is supported by very strong evidence establishing dramatic benefi ts in properly selected patients. The study by Davey and colleagues 12 does suggest that bronchoscopic lung volume reduction might ultimately provide an alternative, albeit one which aff ords a lesser degree of palliation than surgical lung volume reduction, in the few patients with intact interlobar fi ssures. However, we must be careful not to let this fi nding make us forget the great value of surgical lung volume reduction in patients both with and without intact fi ssures. It seems clear that surgery achieves improvements that are substantially higher than bronchoscopic lung volume reduction will ever be able to achieve-even in the most ideal candidates for bronchoscopic lung volume reductionand surgery might not even be more morbid.
